Total
0
Shares
Advanced Human Imaging (ASX:AHI) - CEO, Vlado Bosanac
CEO, Vlado Bosanac
Source: Advanced Human Imaging
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Advanced Human Imaging (AHI) sees a “very promising” relaunch of Tinjoy’s The Health Cube
  • The marketing relaunch has generated 30,000 new preregistrations, which now total more than 144,000
  • AHI is pleased with the progress of the relaunch, with Tinjoy targeting one million users by Christmas
  • On the market, AHI is down 9.09 per cent, trading at $1.30 per share at 12:44pm AEST

Advanced Human Imaging (AHI) has seen a “very promising” relaunch of Tinjoy’s The Health Cube.

Earlier this year, AHI signed an agreement with Tinjoy Biotech to integrate AHI’s BodyScan and FaceScan technology into Tinjoy’s WinScan app.

The Health Cube marketing relaunch has generated 30,000 new preregistrations, with total preregistrations currently at 144,391.

The Health Cube relaunch was undertaken in preparation for the introduction of the WinScan app.

In July, the company did a pilot launch of The Health Cube platform through the network of existing customers of the Tinjoy Group. During this time the platform crashed, but had a successful relaunch on August 12.

AHI is pleased with the progress of the relaunch of The Health Cube, with Tinjoy targeting one million users by Christmas.

AHI CEO and Chairman, Vlado Bosanac, said the Health Cube seemed to be working well and gaining momentum.

“I am looking forward to seeing the pre-registrations convert to active users,” Mr Bosanac said. “The sheer size of the market in China and acceptance of digital engagement is proving to be a very positive outcome for the partnership.

“Clearly, China is a very health conscious and technology friendly community. The key steps from here are to launch the application, and commence the consumer growth and acquisition plan Tinjoy are successfully executing.”

Director of Tinjoy Russell Bateman said the post COVID-19 world in China was focused on health.

“We really wanted to be getting deeply embedded with our user base before now,” Mr Bateman said. “The opportunity to perfect the user experience has, however, been invaluable. Consumers in China have a high expectation for digital performance, and we did not want to disappoint the millions of people who interact with Tinjoy every day.

“We now sit with a product that is very much in-tune with where the market is right now.”

On the market, AHI is down 9.09 per cent, trading at $1.30 per share at 12:44pm AEST.

AHI by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.